Kynurenine 3-monooxygenase (KMO) regulates levels of neuroactive kynurenine pathway metabolites associated with neurodegeneration. Its inhibition ameliorates disease phenotypes in animal models but current inhibitors are not brain permeable. Through structure-based virtual screening and compound synthesis, Zhang et al. now develop KMO inhibitors that can enter the rodent brain to modulate metabolism in this pathway.
- Shaowei Zhang
- Michiyo Sakuma
- Nigel S. Scrutton
